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Port-A-Cath Insertions in Acute Leukaemia and 
Childhood Malignancies
Amos H.P. Loh and Chan-Hon Chui, Department of Paediatric Surgery, KK Women’s and 
Children’s Hospital, Singapore.
OBJECTIVE: This retrospective case series sought to determine the incidence and profile of catheter-related
complications associated with Port-A-Cath insertions in paediatric cancer patients, as well as predictive
factors for infection-related port removals.
METHODS: Between January 2002 and December 2004, 175 consecutive Port-A-Cath insertions were
followed for a total of 75,000 days (median, 407; range, 6–1,074). Incidence of catheter-related bloodstream
infections (CRBSIs), other complications and CRBSI-related port removals were analysed for cases with
acute leukaemia versus other malignancies.
RESULTS: A total of 33 CRBSIs were encountered in 26 cases (18.9%), an infection rate of 0.44 episodes
per 1,000 catheter days. While mean preoperative platelet count was 125.34 × 109/L in children with acute
leukaemia and 392.11 × 109/L in those with other malignancies (p < 0.01), the incidence of all complications
were similar between both subgroups. Staphylococcus epidermidis (23.1%) and Klebsiella spp. (19.2%) were
most commonly isolated from infected ports. Median patient age and duration of implantation in CRBSI-
related port removals was 1.5 years and 111 days respectively, and 10.0 years and 414 days respectively in
CRBSIs without port removal.
CONCLUSION: Minimal complications are associated with Port-A-Cath insertions, even in thrombocy-
topaenic leukaemic patients. The dominance of Gram-negative organisms in CRBSIs parallels the chang-
ing trend of nosocomial infectious agents involved in catheter-related infections. [Asian J Surg
2007;30(3):193–9]
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Introduction
In the management of children with cancer, long-term
indwelling central venous access devices provide an unob-
trusive yet reliable access route for the regular administra-
tion of cytotoxic drugs, antibiotics, blood products other
intravenous medications and the collection of blood sam-
ples.1,2 The tunnelled, cuffed, silastic central venous catheter
pioneered by Broviac and colleagues3 and later modified
by Hickman and colleagues4 provided such an access route
for use in adults and children but regularly led to high
rates of catheter-related bloodstream infections (CRBSIs)
of 31–43%.5,6 Later development of the Port-A-Cath totally-
implantable central venous access port obviated the need
for the persistent open skin wound in the former devices,
and correspondingly demonstrated improved CRBSI rates
in early series. Still, catheter-related infections — among
other associated complications — remain the main challenge
for centres using the Port-A-Cath and similar devices.
From 1995 through 2000, the pooled mean CRBSI rate
for all paediatric intensive care units (ICUs) reporting
data to the National Nosocomial Infection Surveillance
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System (NNIS) of the Centre for Disease Control was 7.7
per 1,000 catheter days.7 As in adults, the majority of
CRBSIs in children were caused by coagulase-negative
staphylococci. During 1992–1999, these bacteria accounted
for 37.7% of bloodstream infections in paediatric ICUs
reporting to the NNIS. Gram-negative bacteria accounted
for 25% of infections, and enterococci and Candida spp.
accounted for 10% and 9%, respectively. Published series of
Port-A-Cath use in childhood cancer report greatly varying
frequencies of CRBSIs, with some strongly supporting their
use in view of low infection rates,8,9 and others considering
these infections to be relatively frequent.10,11 Using existing
definitions for CRBSIs,12 this study sought to determine the
incidence and profile of complications as well as possible
predictive factors for infection-related port removals associ-
ated with the insertion and use of the Port-A-Cath in our
unit. Subgroup analysis was carried out for cases with acute
leukaemia and those of other malignancies.
Patients and methods
We retrospectively reviewed the medical records of 175
surgical implantations of Port-A-Cath devices in paedi-
atric oncology patients during the 3-year period from 
1 January 2002 to 31 December 2004 at KK Women’s and
Children’s Hospital, Singapore. In our centre, all paediatric
oncology patients requiring chemotherapy receive a Port-
A-Cath device, unless refused or surgically contraindi-
cated. Early insertion of ports is exercised, in particular in
children with newly diagnosed acute leukaemias—often
within the first week of diagnosis. The only type of
implanted access port used in this study was the single
lumen Port-A-Cath II System with attached polyurethane
catheter (SIMS Deltec Inc., St Paul, MN, USA). The ports
are composed of a light-weight contoured polysulfone
casing surrounding a titanium port reservoir, with a
polyurethane catheter. Catheter introducer sizes were 5.8 or
7.8 Fr (internal diameter of 1.0 mm or 1.6 mm respectively),
and either standard-sized or low-profile ports were used
depending on patient size.
Devices and their use
All Port-A-Cath implantations were performed under gen-
eral anaesthesia in the sterile operating theatre environment
by surgeons from the same paediatric surgery department
using an identical technique. The ports were inserted using
Seldinger’s technique through the subclavian vein via an
infraclavicular approach, and anchored to the underlying
pectoralis fascia within a subcutaneous pouch. Intraoper-
atively, no perioperative antimicrobial prophylaxis was
administered. Postoperatively, all dressings, needles and
lines placed at the time of surgery were left in situ until the
next change of needle, and a single set of baseline blood
cultures were drawn immediately after surgery by accred-
ited doctors or nurse clinicians.
Thereafter, for the duration of retention of the ports,
they were accessed or flushed at least once every 4 weeks.
Trained doctors would access the devices using sterile
technique, and upon demonstrating good backflow from
the port, would flush it with 7 mL of 100 U/mL heparinized
saline. During periods of prolonged continuous use, the
port needles were changed every 7 days strictly, with tubings
changed every 3 days. Except when technical difficulties
such as port blockage or local infection were encountered,
the ports were used for all doses of chemotherapy and for
the majority of blood sampling procedures when required.
In the event of port failure, multilumen tunnelled catheters
were implanted until a new port could be resited.
Definitions
CRBSI was defined as any episode of sepsis presenting
with clinical features of bloodstream infection, with com-
pelling evidence that the infection at the port site and in the
peripheral blood were related, as demonstrated by growth
of identical organisms in qualitative blood cultures from
peripheral blood and from the port, in the absence of any
other identifiable source for the infection.13 As per proto-
col, paired blood cultures from peripheral veins and
catheters were drawn at first presentation of all septic
episodes before first-line antibiotics ceftriaxone and gen-
tamicin were started. Differential time to positivity was not
measured consistently in all cases and hence was not used
as a definition for CRBSI diagnosis.
Definition of Port-A-Cath-related local infections
included clinical infections of the tunnel or subcutaneous
pocket, as well as isolated skin infections over the port site.
All such episodes were managed with local wound care and
temporary cessation of port-site access to allow recovery
of local skin and soft tissues. Infections occurring within
the immediate 30 postoperative day period were considered
a marker for procedure-related infection. Indications for
removal of Port-A-Caths included successful completion
of chemotherapy, persistence of clinical sepsis and positive
blood cultures despite persistence of appropriate antibiotic
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therapy, and mechanical complications such as malposition
and persistent obstruction refractory to urokinase.
Results
During the 3-year study period, 175 Port-A-Cath insertions
were performed in 159 paediatric cancer patients undergo-
ing chemotherapy. Median age at surgery was 5.52 years
(range, 55 days – 16.9 years), and 102 (58%) cases were male
and 73 (42%) were female. The racial distribution of cases
was similar to the local general population: 116 (66%)
were Chinese, 34 (19%) were Malay, 11 (6%) were Indian,
and 14 (8%) were of other ethnic groups.
Acute leukaemias made up half of the study group with
88 cases, with the other group comprising 87 cases of all
other cancer diagnoses. The demographics of both groups
did not differ significantly. Acute lymphoblastic leukaemia
was the most common diagnosis (43.4%, n = 76). This was
followed by central nervous system tumours (medulloblas-
toma, astrocytoma, pineal gland tumours, optic gliomas;
9.71%, n =17), acute myelogenous leukaemia (6.86%, n =12),
lymphomas (6.29%, n = 11), chronic or relapsed leukaemias
and rhabdomyosarcoma (5.71%, n = 10 each), neuroblas-
toma and bone tumours (osteosarcoma, Ewing’s sarcoma;
4.57%, n = 8 each), germ cell tumours (4.00%, n = 7), hepa-
toblastoma (2.29%, n = 4), Wilm’s tumour (1.71%, n = 3),
ependymoma, pulmonary blastoma and nasopharyngeal
carcinoma (1.14%, n = 2 each), histiocytosis, adrenocortical
carcinoma and retinoblastoma (0.57%, n = 1 each).
Mean preoperative platelet counts in children with
acute leukaemia were 125.34 × 109/L versus 392.11 × 109/L
in those with other malignancies (p < 0.01). Other preop-
erative coagulation parameters were similar in both sub-
groups (Table 1). Median and total observation time for
the implanted ports were 407 (range, 6–1,074) and 75,000
catheter days, respectively.
In all, 109 clinical episodes of sepsis were recorded in
65 patients. Of these, 33 episodes fulfilled the definition
of CRBSI and occurred in 26 (16.4%) patients, 21 of whom
experienced only one CRBSI episode, three experienced
two episodes, and two experienced three episodes during
the entire observation period. Selecting for CRBSI episodes
during the immediate 30 postoperative days—a marker
for procedure-related infection—nine episodes were encoun-
tered in nine patients (5.7%). This gave an infection rate
of 0.44 CRBSI episodes per 1,000 catheter days overall,
and 1.73 episodes per 1,000 catheter days for the immediate
30 postoperative day period. A further 55 episodes of sep-
sis were recorded in 42 (26.4%) patients with only positive
port cultures but negative peripheral cultures; these did not
fulfil the study definition of CRBSI and were considered
separately. Patients who had episodes of CRBSI did not
differ significantly from those who did not have CRBSI
episodes in terms of age, gender, ethnic group, and oper-
ating surgeon. Procedure-related details (number of
guidewire passes, catheter size, port profile) were also
unrelated to CRBSI incidence.
The incidence of CRBSI was only slightly lower in acute
leukaemic patients (17.0%, 15 CRBSI episodes), compared to
those with other malignancies (20.7%, 18 CRBSI episodes).
For CRBSIs occurring in the immediate 30 postoperative
day period, no significant difference was found between the
acute leukaemics and those with other malignancies (4.6%, 
4 episodes vs. 5.8%, 5 episodes). Non-catheter-related clini-
cal bloodstream infections with only positive blood cultures
from the port were noted more frequently in acute leuk-
aemic patients (39.8%, 35 positive cultures in 27 cases) as
compared to those with other malignancies (23.0%, 20 posi-
tive cultures in 15 cases), but with a difference that did not
reach statistical significance (p = 0.69). There was no signifi-
cant difference in the incidence of other mechanical and
local port-site complications in both subgroups (Table 2).
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Table 1. Preoperative blood parameters
Acute leukaemia Other malignancies Total p
Mean preoperative blood parameters
Platelet count (×109/L) 125.34 392.11 257.97 < 0.01
INR 0.98 0.88 0.93 0.25
aPTT (s) 27.19 25.60 26.40 0.64
PT (s) 17.56 17.31 17.44 0.64
INR = international normalized ratio; aPTT = activated partial thromboplastin time; PT = prothrombin time.
Overall, 154 individual bacterial cultures were isolated
from paired Port-A-Cath blood samples. Methicillin-
resistant Staphylococcus epidermidis (MRSE) was the most
commonly detected organism (24.7%, 38 detections), fol-
lowed by Pseudomonas aeruginosa (15.6%, 24 detections) and
Klebsiella spp. (13.6%, 21 detections). Selecting for blood
cultures taken only during CRBSIs, MRSE was still the most
commonly isolated organism (23.1%, 12 detections), fol-
lowed by Klebsiella spp. (19.2%, 10 detections), methicillin-
sensitive Staphylococcus aureus (MSSA) (13.5%, 7 detections),
and P. aeruginosa and Enterococcus faecalis (11.5%, 6 detections
each). Among acute leukaemic patients, 93 bacterial cul-
tures were isolated from 77 paired samples. P. aeruginosa
was the most commonly detected organism (21.5%, 20 cul-
tures), followed by MRSE (20.4%, 19 cultures). Among the
non-leukaemic patients, MRSE remained the most com-
monly detected in 10 patients. For blood cultures taken
during CRBSIs, P. aeruginosa, MRSE and MSSA were the
most common organisms in the acute leukaemic group
(20.8% each), as compared with MRSE and Klebsiella spp.
(25.0% each) among the non-leukaemics.
By the end of the study period, 29 (16.6%) ports were
removed due to successful completion of chemotherapy,
10 (5.7%) ports were removed due to CRBSI, and two
ports (1.1%) each were removed due to blockage and mal-
position. Thirteen (7.4%) patients had died with their
ports, 112 (64.0%) ports still remained in situ, and seven
(4.0%) were lost to follow-up. Overall complication-
related Port-A-Cath removals (i.e. resulting from CRBSI,
local infection, blockage or malposition) were identical
among the acute leukaemic and non-leukaemic groups
(4.0%, 7 removals each). The 10 CRBSI patients requiring
port removal were younger at the time of surgery (median
age, 2.32 years; range, 1.2–16.8 years) compared to the
other 23 CRBSI patients who did not require port
removal (median age, 10.0 years; range, 1.2–15.3 years).
Also, the former 10 cases were associated with a shorter
time from implantation to CRBSI (median, 111 days; range,
26–361 days) compared to the latter 23 cases (median, 414
days; range, 71–1,037 days). MRSE (coagulase-negative
staphylococci) was associated with five of the CRSBI
removals, and MSSA, methicillin-resistant S. aureus, P. aerug-
inosa, Klebsiella pneumoniae and Candida parapsilosis with
another one case each.
Discussion
This study reflects results from the largest recorded series
of Port-A-Caths implanted in paediatric cancer patients
from a single institution. The low overall CRBSI rate of
0.43 per 1,000 catheter days achieved in this series was
comparable with most existing studies despite the unit’s
practice of early placement of ports in acute leukaemic
patients. Nevertheless, 10 cases (5.7%) in the series still
sustained port-related bloodstream infections that
resulted in therapeutic port removal. In our study, young
age and shorter implanted duration appeared to play a
role as a predictive factor for infection-related port
removals, with all observed cases of CRBSI-related port
removals occurring within the first year of implantation.
This observation has been echoed in similar series where
other host factors such as intensive chemotherapy, severe
neutropaenia and frequent use of the port—more often
observed in the said groups—have been postulated as key
predictive factors for CRBSI-related port removals.14
The predominant CRBSI-causing organism detected
in our series was S. epidermidis, a common skin commen-
sal that, with other coagulase-negative staphylococci, has
been regularly observed in most studies to be the most
frequent cause of CRBSIs. However, the second line 
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Table 2. Complications encountered in 175 Port-A-Caths
Acute leukaemia Other malignancies Total
p
(n= 88) (n= 87) (n= 175)
Complications, n (%)
CRBSI 15 (17.0) 18 (20.7) 33 (18.9) 0.93
Haematoma 2 (2.3) 0 (0) 2 (1.1) 1.00
Port blockage 4 (4.6) 1 (1.2) 5 (2.9) 0.75
Local infection 4 (4.6) 1 (1.2) 5 (2.9) 0.75
Malposition 0 (0) 2 (2.3) 2 (1.1) 0.88
CRBSI = catheter-related bloodstream infection.
of organisms identified in our CRBSIs present a more
worrying trend. S. aureus and enterococci have been iden-
tified in the past two decades to be the second most com-
mon CRBSI-causing organisms,7 with Gram-negative
bacilli constantly accounting for only less than 20% of
CRBSIs.15 Our findings demonstrated a reverse in that
trend, with Klebsiella spp. and P. aeruginosa accounting for
nearly an equal number of cases compared to S. epidermidis.
In fact, P. aeruginosa was the most commonly detected
organism in the acute leukaemic subgroup. Furthermore,
methicillin resistance in first line organisms—a rarity in
studies from earlier decades—was observed to be the norm
in our study.
The migration of skin flora through the cutaneous
insertion site is an established mechanism of infection
that accounts for bacterial contamination of the catheter
hub and subsequent intraluminal infection by Gram-
positive organisms, in particular coagulase-negative
staphylococci. Alternative mechanisms such as increased
translocation of endogenous gut bacteria has also been
observed, particularly in neutropaenic patients with
altered mucosal barriers,16 and such mechanisms could
account for our finding of a higher prevalence of Gram-
negative CRBSIs among acute leukaemics. As with other
units, our current efforts at CRBSI-reduction are anchored
largely on the basic fundamentals of skin barrier sterility
and integrity.17 However, this study’s finding may suggest
the inability of rigorous skin antisepsis regimens alone to
eradicate CRBSIs in this patient group.
While a higher rate of CRBSIs was detected in the
immediate 30 postoperative day period, these occurred at
near-equal frequency among the acute leukaemias and
other malignancies, suggesting that our practice of early
insertion of Port-A-Caths in acute leukaemics did not
affect early postoperative infectious morbidity. However,
both episodes of postoperative bleeding encountered in
this series were from the former subgroup. One case of
acute lymphoblastic leukaemia developed a port-site
haematoma 16 days after insertion; the other, a case of
acute myelogenous leukaemia, developed a haematoma
on postoperative day 5. Preoperative platelet counts in
both were not critically low—60 × 109/L in the former and
123 × 109/L in the latter—and both ports remained usable
after initial application of pressure dressings to tampon-
ade bleeding.
Difficulties faced included the selection of an appropri-
ate CRBSI study definition as well as the comparison of
infection rates with other studies. This was due to the lack
of consensus and resulting multitude of different CRBSI
definitions in existing publications, particularly the smaller
single-centre series.18–20 While a truly equivalent compari-
son of CRBSI rates was not possible, our overall CRBSI rate
compared favourably against the other sizable series that
used similar definitions (Table 3).9–11,21–26 A common 
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Table 3. Port-related infections in paediatric cancer populations, a review of the literature
Author Ports, Total Mean port 
CRBSI rate 
(year of publication) n port days days/patient
CRBSI (per 1,000 CRBSI definition
PAC days)
This study (2007) 175 75,000 407* 32 0.43 Sepsis with positive port 
Ross et al (1988)21 50 10,478 350 17 1.1 AND peripheral cultures
Hengartner et al (2004)22 155 134,773 738 12 0.11† Sepsis with positive port 
Severien & Nelson (1991)23 25 9,611 384 4 0.42 OR peripheral cultures
Mirro et al (1990)24 93 Not recorded 419 10 0.26‡
Shulman et al (1987)11 31 7,198 232 4 0.69
Tobiansky et al (1997)10 63 13,293 211 15 1.43 Sepsis with positive port 
Becton et al (1988)25 71 16,101 227 23 1.5 culture only
Munro et al (1999)26 149 69,342 399 12 0.17 Infection-related removals only
Wiener et al (1992)9 290 189,495 635 27 0.14
*Median; †repeated detection of same microbial species for ≥ 3 days; ‡fever and bacteraemia that resolved after catheter removal, with
organisms isolated only in port cultures or in peripheral cultures and the removed catheter tip. CRBSI = catheter-related bloodstream infection;
PAC = Port-A-Cath.
discrepancy faced in the diagnosis of CRBSI was the varying
use of paired blood cultures obtained from both peripheral
and port blood versus unpaired blood cultures. Authors
have criticized the value of the paired blood culture sample
in this diagnostic dilemma, citing it to be inconvenient and
not contributing to eventual diagnostic value.27 Analysis of
our data using both definitions found that a slightly higher
frequency of CRBSIs would be diagnosed in the acute
leukaemic group if only port cultures were considered.
The highly heterogeneous presentations and clinical
courses limited our ability to compare potential con-
founders such as intensity and duration of chemotherapy,
and degree of neutropaenia. The study was also limited by
its retrospective design and limited numbers, affecting its
statistical power to make definitive conclusions—a limi-
tation faced by many similar single-centre series. In the
future, a meta-analysis could allow for factor analysis of
pooled data from other published reports using similarly
defined outcome measures.
In summary, our study finds the Port-A-Cath to be a
convenient and safe indwelling vascular access device for
use in paediatric cancer patients. Acceptable and compa-
rable rates of infectious and mechanical complications
were achieved in both acute leukaemia as well as other
cancers, even with early implantation of ports in the rela-
tively more thrombocytopaenic former group. The higher
prevalence of Gram-negative organisms causing CRBSIs
among acute leukaemics parallels the changing trend of
nosocomial infectious agents involved in catheter-related
infections.
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